Media coverage about Relypsa (NASDAQ:RLYP) has been trending positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Relypsa earned a daily sentiment score of 0.31 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.0581718055979 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Relypsa (NASDAQ RLYP) traded down $0.01 during midday trading on Friday, hitting $31.98. 107 shares of the stock were exchanged, compared to its average volume of 2,933,219. Relypsa has a 1 year low of $10.26 and a 1 year high of $32.12.
TRADEMARK VIOLATION WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/01/19/favorable-news-coverage-somewhat-unlikely-to-affect-relypsa-rlyp-share-price.html.
Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.
Receive News & Ratings for Relypsa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa and related companies with MarketBeat.com's FREE daily email newsletter.